# Peter Dines

> Peter Dines is a Series A investor at Mercia Asset Management backing Medical and Health Care. See 19 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Mercia Asset Management](https://shizune.co/investors/profile/mercia-technologies)
- Location: Four Oaks, United Kingdom
- Total investments: 19
- Last investment: Apr 2024
- Lead investor: 68%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/peter-dines-b617423a/
- X (Twitter): https://twitter.com/peterdinesc7
- Website: https://x.com/peterdinesc7
- Facebook: https://www.facebook.com/peter.m.dines

Peter Dines is a Series A investor at Mercia Asset Management in Four Oaks focused on Medical and Health Care. Peter has been involved with a number of high profile turnarounds and exits within the sector, including the acquisition of Surgicraft’s loss making business where, as Managing Director, sales quadrupled within three years and the business was subsequently sold to ISIS Equity Partners. Other key healthcare positions held, both previously andcurrently, include Bridges Ventures, Cisiv, Diagnostic World, Spring Active and Newtech Ortho.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 11% |
| Health Care | 2 | 11% |
| Eyewear | 1 | 5% |
| Software | 1 | 5% |
| Biotechnology | 1 | 5% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 11% |
| Funding Round | 2 | 11% |
| Seed | 1 | 5% |
| Pre-Seed | 1 | 5% |
| Venture - Series Unknown | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Locate Bio | Locate Bio is a regenerative medicine development company focused on orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. We are curious about what is possible, but ground all our work in robust scientific evidence. We relentlessly pursue high-value opportunities with clear unmetclinical needs. | $11.6M | Venture - Series Unknown | Apr 29, 2024 |  |
| Axis Spine Technologies | Axis Spine Technologies is building an expert team to develop highly differentiated products that provide meaningful improvements in patient care. | $12.5M | Series A | Oct 18, 2022 |  |
| Axis Spine Technologies | Axis Spine Technologies is building an expert team to develop highly differentiated products that provide meaningful improvements in patient care. | $12.5M | Series A | Oct 18, 2022 |  |
| Locate Bio | Locate Bio is a regenerative medicine development company focused on orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. We are curious about what is possible, but ground all our work in robust scientific evidence. We relentlessly pursue high-value opportunities with clear unmetclinical needs. | $13.9M | Venture - Series Unknown | Sep 03, 2021 |  |
| Locate Bio | Locate Bio is a regenerative medicine development company focused on orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. We are curious about what is possible, but ground all our work in robust scientific evidence. We relentlessly pursue high-value opportunities with clear unmetclinical needs. | $13.9M | Venture - Series Unknown | Sep 03, 2021 |  |
| Axis Spine | Axis Spine operates as a spinal implant company. Following the patenting of new technologies in the field of dynamic stabilisation, Axis Spine Ltd was put on hold whilst Jon launched ApaTech's Actifuse product and then NuVasive’s extensive range of spinal products, including XLIF, into the UK market. After successfully accomplishing thesegoals, Jon is now building a team to deliver interesting new technologies that provide the surgeon and hospital payer with improved solutions that represent better value to existing problems. | $2.8M |  | Feb 24, 2021 |  |
| Axis Spine Technologies | Axis Spine Technologies is building an expert team to develop highly differentiated products that provide meaningful improvements in patient care. | $3M | Seed | Jan 27, 2021 |  |
| Axis Spine Technologies | Axis Spine Technologies is building an expert team to develop highly differentiated products that provide meaningful improvements in patient care. | $3M | Seed | Jan 27, 2021 |  |
| Locate Bio | Locate Bio is a regenerative medicine development company focused on orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. We are curious about what is possible, but ground all our work in robust scientific evidence. We relentlessly pursue high-value opportunities with clear unmetclinical needs. | $2.8M | Venture - Series Unknown | Jul 20, 2020 |  |
| Locate Bio | Locate Bio is a regenerative medicine development company focused on orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. We are curious about what is possible, but ground all our work in robust scientific evidence. We relentlessly pursue high-value opportunities with clear unmetclinical needs. | $2.8M | Venture - Series Unknown | Jul 20, 2020 |  |

10 of 19 investments shown.

## Co-investors
- [Mercia Asset Management](https://shizune.co/investors/profile/mercia-asset-management) — VC Fund, 11 deals together
- [Mercia Asset Management](https://shizune.co/investors/profile/mercia-technologies) — VC Fund, 9 deals together
- [ACF Investors](https://shizune.co/investors/profile/angel-cofund) — VC Fund, 5 deals together
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund, 3 deals together
- [MedTex Ventures](https://shizune.co/investors/profile/medtex-ventures) — VC Fund, 2 deals together

## About Mercia Asset Management

VC Fund · Henley In Arden, United Kingdom

Mercia Asset Management invest across four distinct asset classes of venture, private equity and debt, referred to as our ‘Complete Capital Solution.Mercia Asset Management ision is to be the first choice for investors, investees and employees and, by aspiring to be the first choice, we believe that Mercia will deliver superior returns for businessowners, shareholders and fund investors alike.

5 contacts available at Mercia Asset Management.

| Name | Title | Profile |
| --- | --- | --- |
| Aaron Lawson-Clark | Investment Director | https://shizune.co/investors/profile/aaron-lawson-clark-d240 |
| Julian Viggars | Chief Investment Officer | https://shizune.co/investors/profile/julian-viggars-829d |
| Martin Glanfield | Chief Financial Officer | https://shizune.co/investors/profile/martin-glanfield |
| Peter Dines | Chief Operating Officer & Head of Life Sciences & Biosciences | https://shizune.co/investors/profile/peter-dines |
| Ashwin Kumaraswamy | Investment Director | https://shizune.co/investors/profile/ashwin-kumaraswamy |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Peter Dines invest in?

Peter Dines invests primarily in Medical, Health Care and Eyewear startups, most often at Series A and Funding Round stage. Most of the 19 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Peter Dines last invest?

The most recent investment recorded for Peter Dines closed in Apr 2024. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co